C
Corami develops a platform that enables targeted delivery of therapeutics directly to cardiac tissue, addressing the difficulty of localized treatment for heart disease. By engineering delivery vectors that home to the heart’s unique physiology, the company aims to improve efficacy and reduce systemic exposure of cardiovascular drugs. Revenue is generated through licensing of its delivery technology and partnership agreements with pharmaceutical firms seeking to enhance cardiac drug pipelines.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- CorAmi develops a platform for targeted delivery of cardiac therapeutics, enabling localized treatment of heart disease. By focusing on precise cardiac targeting, the technology aims to improve efficacy while reducing systemic exposure and side effects. This approach seeks to address the high clinical and economic burden of cardiovascular conditions.